Universal Beteiligungs und Servicegesellschaft mbH Purchases New Stake in Disc Medicine, Inc. (NASDAQ:IRON)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 6,391 shares of Disc Medicine, Inc. (NASDAQ:IRON), valued at approximately $317,000, marking a new investment during the first quarter.
• Several institutional investors notably increased their stakes in Disc Medicine, including FMR LLC, which boosted its holdings by 358.7% during the fourth quarter, now owning over $118 million worth of shares.
• Disc Medicine's recent analyst ratings indicate strong optimism, with an average rating of "Buy" and a price target of $95.73, supported by eleven analysts rating the stock positively.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,391 shares of the company's stock, valued at approximately $317,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Sterling Capital Management LLC grew its stake in shares of Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after acquiring an additional 503 shares in the last quarter. Amalgamated Bank grew its stake in Disc Medicine by 38.6% during the first quarter. Amalgamated Bank now owns 787 shares of the company's stock worth $39,000 after buying an additional 219 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Disc Medicine during the fourth quarter worth about $40,000. Tower Research Capital LLC TRC grew its stake in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after buying an additional 266 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Disc Medicine during the fourth quarter worth about $235,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IRON has been the topic of a number of analyst reports. Morgan Stanley initiated coverage on shares of Disc Medicine in a research note on Thursday, July 3rd. They set an "overweight" rating and a $85.00 price objective on the stock. Raymond James Financial initiated coverage on shares of Disc Medicine in a research note on Wednesday, June 11th. They set a "strong-buy" rating and a $89.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a research note on Thursday, July 3rd. Wedbush restated an "outperform" rating and issued a $90.00 price target on shares of Disc Medicine in a research note on Monday, July 21st. Finally, Truist Financial initiated coverage on shares of Disc Medicine in a report on Monday, July 21st. They set a "buy" rating and a $86.00 price target on the stock. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Disc Medicine presently has an average rating of "Buy" and an average target price of $95.73.

Disc Medicine Trading Up 1.4%

Disc Medicine stock traded up $0.79 during mid-day trading on Friday, hitting $57.86. 134,503 shares of the stock were exchanged, compared to its average volume of 404,650. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $68.73. The firm's fifty day simple moving average is $54.78 and its two-hundred day simple moving average is $51.46. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -14.73 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.41). Analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insider Activity at Disc Medicine

In other news, CEO John D. Quisel sold 34,800 shares of Disc Medicine stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $55.33, for a total value of $1,925,484.00. Following the completion of the sale, the chief executive officer owned 161,828 shares in the company, valued at $8,953,943.24. The trade was a 17.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jean M. Franchi sold 2,031 shares of Disc Medicine stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $59.00, for a total transaction of $119,829.00. Following the completion of the sale, the chief financial officer owned 63,499 shares of the company's stock, valued at $3,746,441. This represents a 3.10% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 108,125 shares of company stock worth $6,234,626. 4.24% of the stock is owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.